actual results and the implementation of the Company's plans to vary materially, including the risks associated with
the initiation, cost, timing, progress and results of the Company's current and future research and development
activities and preclinical studies and clinical trials. These risks are discussed in the Company's filings with the
U.S. Securities and Exchange Commission (SEC), including, without limitation, the Company's Annual Report on Form 10-K
filed on March 15, 2021 and the Company's subsequent filings with the SEC. Except as required by law, the Company
assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in
the future.
Media Contacts:
Bill Berry
Berry & Company Public Relations
W: 212-253-8881
C: 917-846-3862
bberry@berrypr.com
Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com
Investor Contacts:
Matt Lane
Gilmartin Group
617-901-7698
matt@gilmartinir.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 100691
EQS News ID: 1188591
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1188591&application_name=news
(END) Dow Jones Newswires
April 27, 2021 09:00 ET (13:00 GMT)